Loading…
BioNexus Gene Lab Corp. is projected to decline to $2.07 by 2027, a -7% move from its current price of $2.22. BGLC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.16 | $2.22 | $2.28 | -0.04% |
| May 30 | $2.14 | $2.22 | $2.30 | -0.08% |
| May 31 | $2.12 | $2.22 | $2.32 | -0.13% |
| Jun 1 | $2.10 | $2.22 | $2.34 | -0.17% |
| Jun 2 | $2.09 | $2.22 | $2.35 | -0.21% |
| Jun 3 | $2.07 | $2.21 | $2.36 | -0.25% |
| Jun 4 | $2.06 | $2.21 | $2.38 | -0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.06 | $2.21 | $2.38 | -0.30% |
| Week 2 | $2.00 | $2.21 | $2.44 | -0.59% |
| Week 3 | $1.95 | $2.20 | $2.49 | -0.89% |
| Week 4 | $1.90 | $2.19 | $2.53 | -1.18% |
| Week 5 | $1.87 | $2.19 | $2.56 | -1.47% |
| Week 6 | $1.83 | $2.18 | $2.59 | -1.77% |
| Week 7 | $1.80 | $2.17 | $2.62 | -2.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNexus Gene Lab Corp. is a Basic Materials company that focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. It operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers.
BioNexus Gene Lab Corp. (BGLC) trades at $2.22. Its market capitalization is $5.37M, and it is ranked 5263. The price outlook, based on the provided forecast, shows a neutral near term with 2026 having an average price of $2.22 and ROI 0, and a path toward bullish momentum later in the horizon with 2031 avg $2.68 and ROI 20.7, and 2050 avg $5.97 with ROI 168.8.
A major floor 16.5% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 63.8% above — clearing it would confirm fresh momentum.
Key BGLC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BGLC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.08 | Buy | $2.11 | Buy |
| MA 10 | $2.06 | Buy | $2.08 | Buy |
| MA 20 | $2.06 | Buy | $2.09 | Buy |
| MA 50 | $2.21 | Buy | $2.23 | Sell |
| MA 100 | $2.50 | Sell | $2.62 | Sell |
| MA 200 | $3.74 | Sell | $3.24 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.07 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 276.39 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 7.77 | Buy |
| Bollinger %B (20,2) | 1.27 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 70.99 | Sell |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 2.09 | Buy |
| ADX (14) | 16.68 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. The current trend is supported by a 50-day simple moving average of $2.21 and a 200-day simple moving average of $3.74. Key levels to watch are a support at $1.98 and a resistance at $2.28. The 30-day price range spans from $1.86 to $2.65, and annualized volatility sits at 50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.94 | $2.22 | $2.83 | 0% | Neutral | |
| $1.64 | $2.07 | $2.76 | -7% | Neutral | |
| $1.62 | $2.09 | $2.89 | -6% | Neutral | |
| $1.56 | $2.07 | $2.93 | -7% | Neutral | |
| $1.62 | $2.19 | $3.18 | -1% | Neutral | |
| $1.95 | $2.68 | $3.98 | +21% | Bullish | |
| $1.97 | $2.74 | $4.15 | +24% | Bullish | |
| $1.88 | $2.66 | $4.09 | +20% | Neutral | |
| $1.88 | $2.71 | $4.23 | +22% | Bullish | |
| $1.85 | $2.71 | $4.29 | +22% | Bullish | |
| $2.37 | $3.70 | $6.22 | +67% | Bullish | |
| $3.42 | $5.97 | $10.97 | +169% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.94 | $2.22 | $2.60 | +0.00% |
| June 2026 | $1.84 | $2.16 | $2.60 | -2.63% |
| July 2026 | $1.80 | $2.14 | $2.60 | -1.20% |
| August 2026 | $1.83 | $2.18 | $2.69 | +2.21% |
| September 2026 | $1.81 | $2.17 | $2.69 | -0.81% |
| October 2026 | $1.75 | $2.11 | $2.64 | -2.55% |
| November 2026 | $1.78 | $2.16 | $2.71 | +2.23% |
| December 2026 | $1.84 | $2.23 | $2.83 | +3.58% |
Click any year to see its month-by-month BGLC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BGLC to range from $1.94 to $2.83 through 2026. The $2.22 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BGLC price prediction for 2027 points to an average of $2.07 (low $1.64, high $2.76) — a potential decline of -7% on today's $2.22. Price action looks broadly range-bound.
In 2028, BGLC is projected to trade between $1.62 and $2.89, averaging $2.09 — a potential decline of -6% from today's $2.22. That is up +1% on the projected 2027 average. A consolidation phase looks the most probable path here.
BioNexus Gene Lab Corp.'s 2029 outlook centres on $2.07, within a $1.56 to $2.93 range. That is -1% versus the projected 2028 average. That marks a -7% change versus current levels. Price action looks broadly range-bound.
By 2030, BGLC could reach as high as $3.18, with a base case around $2.19 and support toward $1.62 — roughly -1% from $2.22. A consolidation phase looks the most probable path here.
Expect BGLC to range from $1.95 to $3.98 through 2031. The $2.68 average target implies a +21% move from current prices. That is up +22% on the projected 2030 average. Momentum favours further upside here.
The BGLC price prediction for 2032 points to an average of $2.74 (low $1.97, high $4.15) — a potential gain of +24% on today's $2.22. Buyers look set to stay in control over this stretch.
In 2033, BGLC is projected to trade between $1.88 and $4.09, averaging $2.66 — a potential gain of +20% from today's $2.22. That is -3% versus the projected 2032 average. Price action looks broadly range-bound.
BioNexus Gene Lab Corp.'s 2034 outlook centres on $2.71, within a $1.88 to $4.23 range. That is up +2% on the projected 2033 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BGLC could reach as high as $4.29, with a base case around $2.71 and support toward $1.85 — roughly +22% from $2.22. Momentum favours further upside here.
Expect BGLC to range from $2.37 to $6.22 through 2040. The $3.70 average target implies a +67% move from current prices. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BGLC price prediction for 2050 points to an average of $5.97 (low $3.42, high $10.97) — a potential gain of +169% on today's $2.22. Momentum favours further upside here.
Investing $1,000 in BGLC today (≈ 450.45045 BGLC) could be worth
$2,688.08
+$1,688.08 (+169%) by 2050 · US Dollar
Based on the average projected BGLC price of $5.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BGLCwould be worth at today's price.
$1,000 invested in BGLC on May 27, 2025 (≈ 274.725267 BGLC) would be worth
$609.89
-$390.11 (-39.0%) today · 0.61× · US Dollar
Based on a BGLC entry price of $3.64 vs. today's $2.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.09 | $1,062.2 | +6.2% |
| 1 month ago | $2.17 | $1,023.04 | +2.3% |
| 3 months ago | $2.5 | $888 | -11.2% |
| 6 months ago | $4.54 | $488.99 | -51.1% |
| 1 year ago | $3.64 | $609.89 | -39.0% |
| All time (5.0y) ago | $214.8 | $10.34 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BGLC forecast.
Our base-case forecast reaches $4.40 around 2050.
Implied market cap at $4.40: $10.64M
The multi-year forecast shows neutral sentiment through 2030, with 2026 avg $2.22 and ROI 0 and 2030 avg $2.19 with ROI -1.3. Beginning in 2031 the outlook becomes bullish, with 2031 avg $2.68 and ROI 20.7; 2032 avg $2.74 and ROI 23.6; 2034 avg $2.71 and ROI 22.2; 2035 avg $2.71 and ROI 21.9. The horizon extends with strong upside: 2040 avg $3.70 and ROI 66.6; 2050 avg $5.97 and ROI 168.8, with a max of $6.22 in 2040 and $10.97 in 2050.
These figures are forecasts and not guarantees; early years show neutral to modest moves before longer-term upside, and upside potential depends on a range of factors.
Tap a question to reveal the answer.
In 2030 the forecast shows min $1.62, avg $2.19, max $3.18, with ROI -1.3 and Neutral sentiment.
From 2031 onward the forecast is bullish, with 2031 avg $2.68 (ROI 20.7), 2032 avg $2.74 (ROI 23.6), 2040 avg $3.70 (ROI 66.6), and 2050 avg $5.97 (ROI 168.8).
Yes. The 2030 forecast shows a max of $3.18.
Current price is $2.22 and market cap is $5.37M.
2050 min $3.42, avg $5.97, max $10.97, ROI 168.8, sentiment BULLISH.
BioNexus Gene Lab Corp. Community Discussion
0Share your BioNexus Gene Lab Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.